About Nextbiotix
Nextbiotix is a company based in Dijon (France) founded in 2016. Nextbiotix has raised $30.4 million across 6 funding rounds from investors including European Union, Inrae and UI Investissement. Nextbiotix offers products and services including EXL01, EXL02, and EXL03. Nextbiotix operates in a competitive market with competitors including Aclaris Therapeutics, Novozymes, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
- Headquarter Dijon, France
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$30.4 M (USD)
in 6 rounds
-
Latest Funding Round
$3.32 M (USD), Series A
Oct 21, 2025
-
Investors
European Union
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Nextbiotix
Nextbiotix offers a comprehensive portfolio of products and services, including EXL01, EXL02, and EXL03.
Activates NOD2 pathway for treating inflammatory and cancer diseases.
Potential therapy for related infectious diseases.
Additional immunomodulator for targeted treatments.
People of Nextbiotix
Unlock access to complete
Unlock access to complete
Funding Insights of Nextbiotix
Nextbiotix has successfully raised a total of $30.4M across 6 strategic funding rounds. The most recent funding activity was a Series A round of $3.32 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nextbiotix
Nextbiotix has secured backing from 10 investors, including venture fund and institutional investors. Prominent investors backing the company include European Union, Inrae and UI Investissement.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
UI Investissement is engaged in private equity and investment services.
|
Locked | Locked | Locked | |
|
Venture capital investments are managed by Auriga Partners in France.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for Nextbiotix
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nextbiotix
Investment portfolio details for Nextbiotix
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nextbiotix
Detailed financials for Nextbiotix
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nextbiotix Comparisons
Peer comparison for Nextbiotix
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nextbiotix
Nextbiotix operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Novozymes, Escient Pharmaceuticals, Nimbus Therapeutics and Alpine Immune Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Novel dermatologic therapies are developed for skin conditions.
|
|
| Locked | Locked | Locked |
Biosolutions and enzymes are developed for biotechnology applications across industries.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
|
| Locked | Locked | Locked |
Developer of immunotherapies to treat cancer and autoimmune disorders
|
|
| Locked | Locked | Locked |
GPCR drug discovery platform is developed for multiple diseases.
|
Detailed competitors of Nextbiotix
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nextbiotix
Complete news archive for Nextbiotix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nextbiotix
Nextbiotix was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Nextbiotix is headquartered in Dijon, France. It is registered at Dijon, Bourgogne-franche-comte, France.
Nextbiotix is a funded company, having raised a total of $30.4M across 6 funding rounds to date.
Nextbiotix was founded in 2016 and is based in Dijon, France, within the biotechnology sector. Focus is placed on developing live biotherapeutics targeting inflammatory bowel diseases, including Crohns disease and ulcerative colitis. The lead candidate consists of a mono-strain formulation of Faecalibacterium prausnitzii, which exhibits anti-inflammatory properties and influences gut immune activity. Operations remain in the preclinical phase.
Nextbiotix's top competitors include Novozymes, Escient Pharmaceuticals and Nimbus Therapeutics.
Nextbiotix offers EXL01, EXL02, and EXL03.
Nextbiotix has 10 investors. Key investors include European Union, Inrae, UI Investissement, Biocodex, and Crescent Enterprises.